Key facts
- Notable investors include Enterprise Ireland.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for NíoSync
- ·The full record, as it builds
Funding rounds
No funding rounds for NíoSync are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NíoSync
Operator of a commercialization platform intended for specialty biopharmaceutical therapies. The company's platform integrates regulatory navigation capabilities, market intelligence processes, acquisition and distribution workflows, and partnerships across regional stakeholders to manage approval pathways, coordinate multi country launch activities, structure pricing and reimbursement strategies, and support operational implementation at scale, enabling biopharmaceutical developers entering European markets to secure coordinated access, reduce commercial complexity, and achieve predictable, efficient delivery of therapies to patients.
- Sector
- Business Products and Services (B2B)
- HQ
- Dublin, Ireland
- Founded
- 2024
- Employees
- 2
- Website
- niosync.com/
- Ownership
- Privately Held (backing)
NíoSync doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NíoSync shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NíoSync in its N-PORT filings yet. We sweep new filings monthly.